The joint effort will target the development of a resin with high selectivity, high dynamic binding capacity and good chemical, especially caustic, resistance.
Selexis & Teneobio have signed CLAs for the development of Teneobio’s UniAbs™, a new class of multi-specific biologics, for the treatment of multiple myeloma, lymphoma and prostate cancer
Receive JSR Life Sciences news on your RSS reader.